Terry-Ann Burrell is CFO at Beam Therapeutics, a next generation gene editing platform company which she took public in 2020.

Prior to Beam, Burrell spent 11 years with J.P. Morgan, most recently as a managing director in the healthcare investment banking group. There, she had broad coverage across the biotechnology and pharmaceutical industries, helping to execute over $10 billion in equity and equity-linked financings, and more than $50 billion in M&A transactions.